Global Angina Pectoris Drugs Market 2017-2021

Overview of the global angina pectoris drugs market

Technavio’s market study identifies the increase in chronic diseases to be one of the primary growth factors for the angina pectoris drugs market. Angina pectoris is primarily caused by the rising incidences of chronic diseases such as diabetes, high blood pressure, and obesity. Diabetes and high blood pressure increases the risk of developing number of serious health issues related to several vital organs. Obesity is the primary trigger for fatal cardiovascular disorders even if the person does not have diabetes and high blood pressure. According to the angina pectoris drugs market analysis, the market analysts estimate that the market will grow steadily at a CAGR of about 4% by 2021.

Vendors in the market are developing novel therapeutic agents to meet the unmet demand for therapeutics in the angina treatment market. Drugs such as trimetazidine, ivabradine, fasudil, and ranolazine provide new therapeutic treatments for angina pectoris. For instance, Ranolazine is an antianginal agent that has been approved by the FDA for the treatment of angina pectoris and Fasudil can also be used a beneficial adjunctive therapy for the treatment of angina pectoris. These drugs can be safely used by patients that are intolerant to beta-blockers. This launch of novel pharmacologic agents is identified to be one of the key trends contributing towards the growth of the angina pectoris market.

Competitive landscape and key vendors

The angina pectoris drugs market consists of several established drugs manufacturers and pharmaceutical giants offering similar products to the target market. Vendors in the angina pectoris market compete based on aggressive pricing, product efficacy, limited side effects, rich pipeline, and operational base. Hospitals and pharmacies are the major end user of this market

The leading vendors in the market are -

• AstraZeneca
• Gilead
• Novartis
• Pfizer

The other prominent vendors in the market are Bayer HealthCare, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Mylan, and Teva Pharmaceutical.

Segmentation by drug class and analysis of the angina pectoris drugs market

• Beta blockers
• Calcium channel blockers
• Nitrates
• Angiotensin-converting enzyme inhibitors

Beta blockers class of medication is used to manage and treat several heart diseases by reducing the blood pressure, heart rate, and consequently, reducing the workload of the heart. It is also noted that they are competitive antagonists that block the effect of stress hormones such as adrenaline on the heart.

Geographical segmentation and analysis of the angina pectoris drugs market

• Americas
• APAC
• EMEA

Based on the angina pectoris drugs industry insights, the Americas will be the major revenue contributor to this market influenced by factors such as higher prevalence of chronic diseases in the region and better healthcare infrastructure. The high investment in R&D in the cardiovascular healthcare and rising prevalence of angina pectoris will contribute to the angina pectoris drugs market size & share.

Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the global angina pectoris drugs market?
• What are the key market trends impacting the growth of the global angina pectoris drugs market?
• What are the challenges to market growth?
• Who are the key vendors in the global angina pectoris drugs market?
• What are the market opportunities and threats faced by the vendors in the global angina pectoris drugs market?
• Trending factors influencing the market shares of the Americas, APAC, and EMEA.
• What are the key outcomes of the five forces analysis of the global angina pectoris drugs market?

Technavio also offers customization on reports based on specific client requirement.